



## Press Release

### US Patent Granted for CILIAN production platform

**Münster, Germany, May 16 2006:**

Cilian AG today announced that it has received notice from the United States Patent Office that Patent US 7,045,330 B2 has been granted under the Patent Cooperation Treaty (PCT). This patent addresses the DNA sequences of the enzyme phospholipase A1 of Ciliate Tetrahymena, and the use thereof.

This enzyme is key as a signal peptide for the production of proteins in the Ciliate expression platform.

“This is the first patent for our signal peptide” said Dr. Marcus Hartmann, CSO of CILIAN “Our worldwide Intellectual property strategy has been very successful and we are pleased to announce such an important patent for our novel lead program.” Remco Brandt, M.Sc., CEO of CILIAN added, “Since its inception CILIAN has invested tremendous amounts of time and effort in this new and excellent platform. With the granting of this first US patent we enhance the value of the company and we will continue to do so.”

#### **About Cilian AG**

Founded in 2001 by Marcus Hartmann and partners, Cilian is an emerging biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of enzymes and therapeutic proteins. Besides the expression platform Ciliates are also the basis for a new enzyme preparation, which will be developed by the company for the enzyme replacement therapy in the case of maldigestion. Leveraging the unique capabilities of the Ciliates, the Company aims to produce proteins at an unmatched quality and price, thereby fulfilling its mission to improve human health by facilitating access to biopharmaceuticals.

For further information, visit [www.cilian.com](http://www.cilian.com) or contact:

**Cilian AG:**

Marcus Hartmann, Ph.D. (CSO)

tel. +49 251 6 20 310

[hartmann@cilian.de](mailto:hartmann@cilian.de)

The  
United  
States  
of  
America



**The Director of the United States  
Patent and Trademark Office**

*Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.*

*Therefore, this*

**United States Patent**

*Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.*

*If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.*

*If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extensions.*

*Jon W. I. Dudas*

*Director of the United States Patent and Trademark Office*



US007045330B2

(12) **United States Patent**  
**Hartmann et al.**

(10) **Patent No.:** **US 7,045,330 B2**  
(45) **Date of Patent:** **May 16, 2006**

(54) **DNA SEQUENCE OF THE ENZYME  
PHOSPHOLIPASE A1 OF CILIATE  
TETRAHYMENA, AND THE USE OF THE  
SAME**

(75) Inventors: **Marcus Hartmann**, Münster (DE);  
**Marco Grenningloh**, Mainz (DE);  
**Arno Tiedtke**, Münster (DE)

(73) Assignee: **Cilian AG**, Munster (DE)

(\* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/466,110**

(22) PCT Filed: **Jan. 22, 2002**

(86) PCT No.: **PCT/EP02/00578**

§ 371 (c)(1),

(2), (4) Date: **Dec. 31, 2003**

(87) PCT Pub. No.: **WO02/057459**

PCT Pub. Date: **Jul. 25, 2002**

(65) **Prior Publication Data**

US 2004/0115673 A1 Jun. 17, 2004

(30) **Foreign Application Priority Data**

Jan. 22, 2001 (DE) ..... 101 05 152

(51) **Int. Cl.**

**C12N 9/20** (2006.01)

**C12N 1/20** (2006.01)

**C12N 15/00** (2006.01)

**C07H 21/04** (2006.01)

(52) **U.S. Cl.** ..... **435/198**: 435/252.3; 435/320.1;  
536/23.2

(58) **Field of Classification Search** ..... 435/198,  
435/252.3, 320.1; 536/23.2

See application file for complete search history.

(56) **References Cited**

**FOREIGN PATENT DOCUMENTS**

JP 10 155493 6/1998

**OTHER PUBLICATIONS**

Guberman et al., "A method for the preparation of  
*Tetrahymena thermophila* phospholipase A<sub>1</sub> suitable for  
large-scale production", *Journal of Applied Microbiology*,  
86 (1999), 226-230.

Hartmann et al., "Screening for and characterization of  
phospholipase A<sub>1</sub> hypersecretory mutants of *Tetrahymena  
thermophila*", 54 (2000), 390-396.

J. Florin-Christensen, et al., "Phospholipase A<sub>1</sub> and  
Triacylglycerol Lipase: Two Novel Enzymes From  
*Tetrahymena* Extracellular Medium," *Comp. Biochem.  
Physiol.*, vol. 85B, No. 1, pp. 149-155, 1986,  
[XP001053004].

*Primary Examiner*—Tekchand Saidha

(74) *Attorney, Agent, or Firm*—Jacobson Holman PLLC

(57) **ABSTRACT**

A nucleic acid coding for the phospholipase A<sub>1</sub> from ciliates.  
In particular, the phospholipase A<sub>1</sub> has the amino acid  
sequence SEQ ID No. 7.

**10 Claims, 4 Drawing Sheets**